LPCN Lipocine Inc.

-0.05  -3%
Previous Close 1.86
Open 1.88
Price To Book 4.53
Market Cap 43220896
Shares 23,878,948
Volume 24,636
Short Ratio
Av. Daily Volume 430,501

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released September 2016. End of Phase 2b meeting with FDA planned 1Q 2018.
LPCN 1111
Oral testosterone product
CRL issued June 2016. Further CRL issued May 9, 2018. Data from ambulatory blood pressure trial due 1Q 2019.
LPCN 1021
Men with low testosterone (Low T)
Conduct food/fact effect study 2H 2018 in preparation for Phase 3 trial.
LPCN 1107
Prevention of preterm birth ("PTB").
Presentation at EASL April 11, 2019 9am CEST.
LPCN 1144
Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)

Latest News

  1. LPCN: Turning the Tables
  2. Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy
  3. LPCN: ABPM Study Topline Data
  4. Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy
  5. Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers
  6. Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference
  7. LPCN: NASH Topline
  8. Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019
  9. Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate
  10. Lipocine's LPCN 1144 for NASH Demonstrates Substantial Fatty Liver Resolution and Meaningful Liver Fat Reduction in NAFLD Population
  11. Lipocine Announces Financial and Operational Results for the Year Ended December 31, 2018
  12. Does Lipocine Inc.’s (NASDAQ:LPCN) CEO Pay Reflect Performance?
  13. Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
  14. LPCN: Soldiering on and Winning Some Battles
  15. 4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19)
  16. Lipocine Files IND To Evaluate LPCN 1144 In Biopsy Confirmed NASH Subjects
  17. Lipocine's NASH Candidate Shows Promise In Liver Fat Study
  18. Lipocine's NASH Therapy Candidate Achieves Meaningful Liver Fat Reduction Based on Interim Results
  19. USPTO Grants Priority Motion To Lipocine And Enters Judgment Against Clarus